title: Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
abstract: Zoledronic acid is known to induce a transient acute phase response (APR). The aim of the study was to investigate whether an APR caused by zoledronic acid administration can induce insulin resistance in post-menopausal osteoporotic women and the potential involvement of different inflammatory markers, cytokines and adipokines to this response. Insulin resistance was calculated by the homeostasis model assessment (HOMA-IR). APR symptoms appeared in 30 post-menopausal osteoporotic women within 24 h and attenuated on day 3 after zoledronic acid infusion. Twenty-eight age- and body mass index-matched, patients without an APR following zoledronic acid administration, served as a control group. In patients with APR, concurrently with a significant increase in serum high sensitive C-reactive protein (hsCRP), interleukin-6 (hsIL-6), tumour necrosis factor-alpha (hsTNF-α) and cortisol levels on days one and two, serum insulin was also significantly elevated, resulting in an increased HOMA-IR. Leptin and resistin significantly increased on day two in contrast to adiponectin which declined, though not statistically significant. The alterations in HOMA-IR were mainly associated to the increase of hsCRP and leptin. In conclusion, zoledronic acid induces an acute, short term insulin resistance, due to an APR, by altering the levels of various adipokines and cytokines.
authors.affiliation: B' Endocrine Unit, Alexandra Hospital , 11528 Athens , Greece.
authors.forename: Georgia
authors.initials: G
authors.lastname: Kassi
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Papamichael
authors.forename: Garyfallia
authors.initials: G
authors.lastname: Papaioannou
authors.forename: Irene
authors.initials: I
authors.lastname: Giagourta
authors.forename: Stavroula
authors.initials: S
authors.lastname: Thanou
authors.forename: Maria
authors.initials: M
authors.lastname: Triantaphyllopoulou
authors.forename: Evagelia
authors.initials: E
authors.lastname: Zapanti
authors.forename: Fotini
authors.initials: F
authors.lastname: Papandroulaki
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Ktena
authors.forename: Helen
authors.initials: H
authors.lastname: Karga
mesh_terms: D000210:Acute-Phase Reaction / Q000139:chemically induced; D052242:Adiponectin / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002097:C-Reactive Protein / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D007333:Insulin Resistance; D015850:Interleukin-6 / Q000097:blood; D020738:Leptin / Q000097:blood; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D052243:Resistin / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D000077211:Zoledronic Acid
chemical_list: D052242:Adiponectin; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D015850:Interleukin-6; D020738:Leptin; D052243:Resistin; D014409:Tumor Necrosis Factor-alpha; D000077211:Zoledronic Acid; D002097:C-Reactive Protein; D006854:Hydrocortisone
keywords: Adipokines; cytokines; insulin resistance; zoledronic acid